Genmab (Otc) (GMAB) has released an update.
Genmab A/S, a leading biotechnology firm, has actively pursued its share buy-back program, repurchasing shares worth DKK 3.5 billion with a completion target date of December 16, 2024. The company has executed several transactions between March 25 and March 29, 2024, under the program, now holding 981,465 treasury shares, equating to 1.48% of the total share capital. This strategic financial maneuver is executed in compliance with EU regulations, underscoring Genmab’s commitment to enhancing shareholder value.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
